Tesamorelin
Also called Egrifta, Egrifta SV, Egrifta WR.
Tesamorelin has FDA-approved products for specific uses. This page cites 1 source, and the strongest evidence comes from human trials.
- Status
- FDA-approved product exists
- Form
- Injection
- Half-life
- Not modeled
- Strongest evidence
- Human trials
- Cited claims
- 1
- Last updated
- November 6, 2026
What the evidence says
Each claim names the kind of study behind it, what it can't tell you, and where it comes from.
Human trials
In a 26-week randomized trial of 412 adults with HIV and abdominal fat accumulation, tesamorelin reduced CT-measured visceral fat compared with placebo.
Limits: The population was 86% men. This trial measured abdominal visceral fat, not general weight-loss effectiveness or fewer cardiovascular events. Its studied formulation does not make SV and WR interchangeable.
Regulatory status
United States
As of November 6, 2026, Egrifta SV and Egrifta WR are FDA-approved to reduce excess abdominal fat in adults with HIV and lipodystrophy. They are not indicated for general weight loss. SV and WR are not substitutable.